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Summary The binding and biological activity of human TNFm on endothelial and tumour cells has been studied in the presence of monoclonal antibodies (MAbs). In particular, one monoclonal antibody to TNF, (MAb 32) has been identified which failed to inhibit binding and cytotoxicity of TNF. on WEHI-164 tumour cells but which was a potent inhibitor ofTNF.-induced endothelial cell procoagulant activity on bovine aortic endothelial cells. The ability of MAb 32 to inhibit selectively the actions of TNF, on endothelial cells but not
on tumour cells suggests a mechanism for enhancement of the anti-tumour action of TNFa in vivo when in complex with this antibody. Treatment of tumour bearing mice (WEHI-164 and Meth A fibrosarcoma) with TNF<,-MAb 32 complex resulted in a 5- to 10-fold enhancement in the potency of the cytokine in comparison
to free TNF.. Complexes between this cytokine and other MAbs generally resulted in either no effect or inhibition ofTNF. activity in vivo and in vitro. Neither intact MAb 32 nor FAb' fragments of MAb 32 showed
any tumour regressive activity in the absence of TNF,,. The FAb' fragments were equipotent to the bivalent form of the antibody in enhancing TNF<, activity. These data provide evidence that it is possible to segregate the individual biological activities ofTNF. with concomitant enhancement of the tumour regressive activity of the cytokine in vivo.
Tumour necrosis factor (TNFC,) is a product of activated
macrophages in response to infection and during malignancy.
Systemic administration of this cytokine results in haemorr-
hagic necrosis of tumours in vivo (Carswell et al., 1975;
Green et al., 1977) whereas in vitro, it has cytostatic and
cytolytic activity on tumour cells (Helson et al., 1975). In
addition to its 'host-protective' effects, TNF, has been impli-
cated as the causative agent in the pathology associated with
septicemia, cachexia, cerebral malaria and cancer. Although
recombinant TNF,,, has been used therapeutically in cancer
patients, side-effects such as coagulopathy, thrombocyto-
paenia, lymphcytopaenia, hepatotoxicity and renal impair-
ment have limited its application (Creaven et al., 1987;
Kimura et al., 1987; Selby et al., 1987; Naworth & Stern,
1986). The systemic toxicity associated with the administra-
tion ofTNFC, is believed to be, at least in part, a consequence
of its interaction with the endothelium (Bevilacqua et al.,
1986; Nawroth & Stern, 1986; Selby et al., 1987). Further-
more, reducing the ability of TNFC, to bind to endothelial
cells whilst preserving its tumour cytotoxic activity may have
a beneficial outcome in the use of this cytokine thera-
peutically. We describe here a monoclonal antibody to
human TNFCt which significantly enhances the tumour regres-
sion activity of the cytokine (5-10-fold) whilst inhibiting
some of the associated toxic side-effects. In particular, the
antibody has been shown to inhibit the procoagulant activity
of TNF, on endothelial cells whilst having no effect on the
binding of the cytokine to WEHI-164 tumour cells. These
observations may provide the basis for an improved
approach to therapy with this cytokine.
Materials and methods
Animals and tumour cell lines
All experiments were performed using female BALB/c mice
aged 10-12 weeks obtained from the CSIRO Division of
Biomolecular Engineering animal facility. The WEHI-164
fibrosarcoma line was obtained from Dr Geeta Chauhdri
(John Curtin School of Medical Research, Australian
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National University). The Meth A sarcoma lines were
obtained from Dr Elizabeth Richards (Sloan Kettering
Cancer Centre).
Fusions andproduction ofmonoclonal antibodies
A panel of 13 murine monoclonal antibodies (MAbs) against human recombinant TNF was raised and characterised as
previously described (Rathjen et al., 1991). Two monoclonal
antibodies are described here; one is a potent inhibitor of all
the activities of TNF. (MAb 47) and a second unique anti-
body (MAb 32) which selectively inhibits the effects of TNFa
on endothelial cells (see text).
WEHI-164 cytotoxicity assay
Bioassay of recombinant TNFC, activity was performed
according to the method described by Espevik and Nissen-
Meyer (1986). Briefly, WEHI-164 cells were cultured in
RPMI-1640 supplemented with 10% foetal calf serum,
10mM hepes and penicillin-streptomycin. Prior to use in the
assay of TNF activity the cells were harvested, washed in
culture medium once and placed in wells of a 96 well micro-
tray (2 x 104 cells/well). TNF., (Bissendorf Biochemicals
3.2 x I07 unitsmg-') at varying concentrations was then
added to each well. Actinomycin D (5 jigml-') was used to
enhance the cytotoxic action of TNF<,. Monoclonal anti-
bodies were used at 1 tig well. After 20 h in the presence of
TNF and/or MAb MTT (3-(4,5-Dimethylthiazol-2yl)-2,5-
diphenyltetrazolium bromide, 10 L of 5 mg ml - stock) was
added to each well. The cultures were incubated for a further
4 h before the supernatant was carefully removed and the
insoluble precipitate dissolved by the addition of 100fLI of
acidified propan-2-ol to each well. The optical density was
then read at 570 nm with a reference wavelength of 630 nm.
Tumour regression experiments
Subcutaneous tumours were induced by the injection of
approximately 5 x 105 cells (WEHI-164 or Meth A fibrosar-
coma). This produced tumours of diameters of 10 to 15 mm
approximately 14 days later at which time experiments com-
menced. Mice were injected i.p. for four consecutive days with recombinant human TNFCt (0.1 itg-10;Lg) and MAb
(50 ig as ascitic globulin fraction prepared by sodium sul-
phate precipitation) mixed 60min prior to administration.
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Control groups received injections of PBS alone, MAb alone
or control MAb (MAb against bovine growth hormone) with
TNF,. Tumour size was measured daily throughout the
course of the experiment. Statistical significance of the results
was determined by unpaired t-test.
Radioreceptor assays
WEHI-164 cells grown to confluency were scrape harvested
and washed once with 1% bovine serum albumin in Hanks
balanced salt solution (HBSS, Gibco) and used at 2 x 106
cells per assay sample. Bovine aortic endothelial cells (pas-
sage 6) were seeded (4 x 104 cells per well) into 24 well
culture dishes and grown to confluency (3-4 days) in
McCoys 5A medium supplemented with 20% FCS, L-gluta-
mine and penicillin/streptomycin (growth medium). For the
radioreceptor assay, the cells were washed once in growth
medium and then incubated with varying amounts of either
unlabelled TNF. ( -104ng per assay sample) or MAb (10-
fold dilutions commencing 1/10 to I/10 of ascitic globulin)
and '251-TNF (50,000 c.p.m.) labelled using the lactoperox-
idase method as previously described (Aston et al., 1985) for
3 h at 37C in a shaking water bath (WEHI-164 cells) or 1 h
at 37°C in a humidified CO2 incubator (endothelial cells). At
the completion of the incubation 1 ml of HBSS/BSA was
added to the WEHI-164 cells, the cells spun and the bound
1251I in the cell pellet counted. For the endothelial cell assay,
1 ml of growth medium was added to each well and aspirated
followed by the addition of 0.1 ml of 0.1 M sodium hydroxide
to lyse the cells. The cell lysate was then transferred to tubes
for counting of bound 1251I-TNF. Binding that could not be
displace by an excess (1 pg) of unlabelled TNF was con-
sidered to be non-specific. Specific binding was calculated
from total binding minus non-specific binding of triplicate
assay tubes. One hundred per cent specific binding corres-
ponded to 1,500 c.p.m.
Endothelial cell clotting assays
Endothelial cell procoagulant activity (PCA) induction by
TNF<, was determined using bovine aortic endothelial cells
(BAE) according to the procedure of Bevilacqua et al. (1986)
with the following modifications: BAE cells were propagated
in McCoys 5A medium supplemented with 10% FCS, peni-
cillin, streptomycin and L-gutamine in standard tissue culture
flasks and 24-well dishes. TNF<,, treatment of cultures (3fig
ml-') was for 4 h at 37°C in the presence of growth medium
after which the cells were washed and scrape-harvested
before being frozen, thawed and sonicated. Total cellular
PCA was determined in a standard one-stage clotting assay
using normal donor platelet poor plasma to which 100gl of
CaCl2 and 100gLl ofcell lysate was added. The time taken for
clotting to occur was then measured. Statistical significance
was determined by unpaired t-test.
Preparation ofFAb' monoclonal antibodyfragments
Univalent antibody fragments were prepared by digestion of
MAb 32 with agarose immobilised papain (Pierce) according
to the manufacturer's instructions. FAb' and Fc antibody
fragments were separated by protein A-Sepharose affinity
chromatography (Pharmacia) and tested for size and binding
to '25I-TNF<, by electrophoresis and radioimmunoassay
respectively.
Results
Binding ofTNF.-MAb complexes to tumour and endothelial
cells
The binding of TNF<,, to cultured WEHI-164 tumour cells
and bovine endothelial cells in the presence of anti-TNFZ,
MAbs is shown in Figure 1. Unlike MAb 47, which was
found to inhibit TNFm, binding to both cell types, MAb 32
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Figure 1 Binding of '25I-TNF, to WEHI-164 tumour cells and
bovine aortic endothelial cells. (MAb 32, *; MAb 47, 0; Cont-
rol MAb 0). Results are the mean±s.e.m. of triplicate deter-
minations.
only inhibited '25I-TNF,, binding to endothelial cells. This
correlated with the corresponding effects of MAb 32 and
MAb 47 on the cytotoxic effects ofTNF<, on cultured WEHI-
164 tumour cells (Figure 2a). The activity of MAb 47 was
found to be typical of 'inhibitory' antibodies; that is, the
inhibitory activity was consistently observed in both the
endothelial and tumour cell assays. Examination of the
activation of cultured endothelial cells by TNF. in the
presence of MAbs 32 and 47 is shown in Figure 2b. Both
antibodies significantly inhibited the TNFa-induced produc-
tion of procoagulant as determined in the single stage clot-
ting assay (P<0.01). Treatment of endothelial cells with
MAbs 32 and 47 in the absence of TNF, failed to induce
procoagulant activity and therefore had no effect on the
clotting time in the single stage clotting assay (data not
shown). Similarly, neither TNF, nor the antibodies
themselves were cytotoxic to the endothelial cells under the
conditions employed; however, TNF<, clearly stimulated the
induction of procoagulant at these doses.
Enhancement ofTNF,,-induced tumour regression ofMAb 32
TNF,, at a dose of 10jig per injection, co-administered with
a control MAb daily for 4 days to WEHI-164 tumour-
bearing mice caused 50% reduction in tumour size (Figure
3). The degree of tumour regression observed was dose
related such that animals treated with only 1 jg of TNFX per
day failed to show any reduction in tumour size. The tumour
regressive activity of TNF,, was completely inhibited by pre-
complexing the cytokine with anti-TNF. MAb 47 before
injection. In contrast, significant enhancement of tumour
regression (P<0.01) was observed in mice treated with 10;Lg
TNFC, in complex with MAb 32 when compared to control
mice (receiving 10;Lg TNFC, in the presence of a control
MAb). Enhanced tumour regression was also observed in
mice treated with lower doses ofTNF. (1 gg) in the presence
of MAb 32; indeed, at this dose of TNF, in complex with
MAb 32, an equivalent degree of regression was only observ-
ed following the treatment of mice with 10 1tg of non-854 D.A. RATHJEN et al.
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Figure 2 Effect of MAb 32 on TNFx-mediated tumour cell
killing in vitro with cultured WEHI-164 fibrosarcoma cells a, and
induction of endothelial cell procoagulant activity b. (MAb 32,
*; MAb 47, 0; Control MAb 0). Results are the mean ± s.e.m.
of quadruplicate determinations.
complexed TNF. (i.e. with control antibody). At the 0.1 pg
dose of TNF, there was no apparent beneficial enhancement
of tumour regression. Enhancement ofTNFc,-induced tumour
regression by MAb 32 was also observed following the treat-
ment of Meth A solid tumours in vivo (Figure 4). In contrast,
however, the treatment of a Meth A tumour subline grown
as ascites failed to give the observed enhancement response
(data not shown).
FAb' fragments of MAb 32, prepared by papain digestion
and purified on Protein A Sepharose as described in the
Materials and methods, were found to enhance TNF,, induc-
ed tumour regression to the same degree as intact, bivalent
MAb 32 (Figure 5). Neither intact MAb 32 nor FAb' MAb
32 caused tumour regression in the absence of TNF,,.
Discussion
The exploitation of genetic engineering technology has pro-
vided many protein hormones and mediators which may
have clinical application in man; however, it is becoming
progressively apparent that particular immunologically active
recombinant molecules (e.g. TNFCt, IL-1, IL-2, y-IFN etc)
retain high levels of toxicity in vivo. Reduction of the level of
toxicity of such molecules may be a prerequisite for their
more general therapeutic use. Since the toxicity of TNFa may
manifest as a direct result of its interaction with a variety of
receptors on different tissues following systemic administra-
tion, we have examined the possibility of 'restricting' the
specificity of this cytokine to particular receptor subsets with
monoclonal antibodies (MAb). By employing this approach
it is shown that the binding of TNF¢ to different receptors
can be selectively modulated by a particular MAb (MAb 32).
These findings suggest that different regions of the cytokine
are associated with its binding with different receptors and
may account for the significant antibody-mediated enhance-
ment of its activity described here.
Out of a panel of 13 monoclonal antibodies (MAbs)
defining at least six distinct antigenic regions on TNF., one
specificity (MAb 32) has been identified which permits bind-
ing of the cytokine to tumour cell receptors (WEHI-164 cells)
but not to sites on bovine aortic endothelial cells. The
specificity of this MAb is unusual in that other inhibitory
antibodies were characteristically found to block both the
binding of 125I-TNF,, to WEHI-164 tumour cells and to
bovine endothelial cells (see typically MAb 47). In view of
the unique nature of MAb-antigen interactions (i.e. binding
to a single site), interpretation of the distinct binding charac-
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Figure 3 Enhancement of TNF.-mediated regression of WEHI-
164 tumours in vivo by monoclonal antibody. MAb 32, *; MAb
47, *; Control MAb, 0. Mice were treated daily with TNF,
either pre-complexed with MAb 32 (50pg) or after mixing with
control MAb (50 pg). Tumour size was determined daily during
the course of the experiment. The results show the mean ± s.d. %
change in tumour area at the completion of treatment (day 4).
Differences observed between control MAb-TNFa and MAb 32-
TNF, treated groups are significant (P<0.01, unpaired t-test).
Control MAb
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Figure 4 Enhancement of TNF,-mediated regression of Meth A
tumours in vivo by monoclonal antibody. MAb 32, *; Control
MAb, 0. Mice were treated daily with TNFm either pre-
complexed with MAb 32 (50jig) or after mixing with control
MAb (50pg). Tumour size was determined daily during the
course of the experiment. The results show the mean±s.d. %
change in tumour area at the completion of treatment (day 4).
Differences observed between control MAb-TNFa and MAb 32-
TNF, treated groups are significant (P<0.01, unpaired t-test).
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Figure 5 Enhancement of tumour regressive activity of TNF. by
univalent FAb'-fragments of MAb 32. WEHI-164 tumour-bear-
ing mice received a single dose of TNF, (10 g) mixed with one
of the following: control MAb, MAb 32 or FAb' fragments from
antibody MAb 32 or with PBS alone. Antibodies (50pg) were
pre-mixed with TNFX I h prior to injection. One group of
animals also received MAb 32 in the absence of TNFX.
teristics of TNFa-MAb 32 complexes to tumour cell and
endothelial cell receptors indicates that the specificity of these
respective binding sites may be different. Indeed, the exis-
tence of more than one TNF, receptor has recently been
documented (Hohman et al., 1989; Brockhaus et al., 1990).
The selectivity of MAb 32 in inhibiting the binding of TNF.,
to endothelial cells but not to tumour cells was confirmed by
the demonstration that similar effects were observed in the
corresponding bioassays with these cells in culture. Unlike
MAb 32, the inhibitory antibody MAb 47 effectively blocked
both the cytotoxicity ofTNF, on tumour cells and the ability
of the cytokine to induce procoagulant in endothelial cell
cultures.
The actions of TNF., on cultured endothelial cells include
activation of the pathways leading to the de novo induction
of cell surface tissue factor and the loss of cell surface
thrombomodulin (Nawroth & Stern, 1986). The possible in
vivo consequences of these effects include the generation of
thrombin and initiation of coagulation as well as decreases in
activated protein C anti-coagulant activity. The recent
demonstration that anti-tissue factor antibodies or protein C
administration can abrogate some of the in vivo biological
activities of TNF<, (toxic shock) lends support to this view
(Nawroth & Stern, 1986; Taylor et al., 1987; Edgington et
al., 1989). In contrast to the effects of MAb 32 on TNF,
activity in WEHI-164 cells, the antibody has been shown to
be significantly more inhibitory than MAb 47 on the induc-
tion of procoagulant activity in cultured endothelial cells.
The greater inhibitory potency of MAb 32 in the procoagu-
lant assay, as compared with MAb 47 in receptor binding, is
still unclear; however, it has been shown (Brett et al., 1989)
that endothelial cells may have more than one class of TNF<,,
receptor, of which the functionally representative one is
reflected in the bioassay rather than in the radioreceptor
assay (see below).
Predictably, the systemic administration of TNFa-MAb 32
complex would be anticipated to result in selective enhance-
ment of the tumour regressive activity to the cytokine and
possibly in inhibition of its effects on the endothelium. Here
it has been shown that the pre-complexing of TNF. with
MAb 32 results in a significant (up to 10-fold) enhancement
of the tumour regressive activity of the cytokine with no
apparent concommitant increase in TNF toxicity. In con-
trast, other antibody specificities (inhibitory or otherwise)
failed to produce this unique effect. The ability of univalent
FAb' fragments, derived from MAb 32, to also enhance the
cytotoxicity of TNF, in this fashion indicates that the
enhancement phenomenon is independent of antibody bival-
ency or Fc-region mediated effects (Aston et al., 1989).
It is shown here that certain TNF,,-MAb complexes can
selectively bind to particular receptor subtypes in vitro. The
phenomenon is not idiosyncratic to the concentrations of
antibody or cytokine employed, as at high doses of antibody
there is clear segregation of biological activity or binding to
receptors. Similarly, the respective affinities of MAb 32 and
MAb 47 (8.77 and 1.88 x 109 mmol I-) are unlikely to
account for these observations. Other MAbs to TNF<, of
analogous affinity to MAb 32 also failed to segregate the
specificity of the cytokine in this manner. The distinct effects
of MAb 32 on TNFC, activity may account, at least in part,
for the substantial enhancement of anti-tumour activity of
the cytokine against WEHI 164 and Meth A solid tumours in
vivo. That is, when in complex with the cytokine, MAb 32
prevents the binding of TNFC, to the large numbers of recep-
tors represented on the endothelium, whilst at the same time
permitting binding and regression of the tumour itself. There-
fore, in order for this type of hormonal enhancement to
manifest, we propose that the complex must have access to at
least two receptor subtype specificities in vivo: in such an
event, 'restriction' of the mediator to a particular subtype by
the antibody may occur. This mechanism would also account
for the absence of any observed enhancement of cytotoxicity
of TNFC, by MAb 32 on WEHI-164 cells in vitro and the
observed lack of enhancement in the Meth A ascites tumour
model. Previous cases of enhancement of hormonal activity
by specific antisera were primarily attributed to antibody
bivalency or prolongation of hormone half-life in the circula-
tion (reviewed in Aston et al., 1989). The potential benefits to
the patient of circulating autoantibody to cytokines, partic-
ularly in relation to the latter mechanism, have also been
discussed recently (Bendtzen et al., 1990). It has been pro-
posed in these studies that cytokine autoantibody occurs with
high frequency in patients on cytokine therapy and may, in
cases, benefit the patient by acting as a specific 'carrier'
molecule. The recent identification of a natural TNFCt binding
protein (Engelmann et al., 1989), which may have regulatory
effects on the cytokine in vivo and the existence of at least
two structurally distinct receptors (Hohman et al., 1989;
Engelmann et al., 1989; Loetscher et al., 1990; Espevik et al.,
1990), would also lend support to the above hypothesis.
Endothelial cells appear to express two TNF receptors which
mediate different biological effects of TNF (Brett et al.,
1989). It appears that expression of tissue factor in response
to TNF is signalled by a non-G protein linked receptor while
increased vascular permeability in response to TNF occurs
via a G protein-linked receptor. More recent evidence (Tarta-
glia et al., 1991) has further indicated that the two TNF
receptors initiate distinct signalling pathways that result in
the induction of different cellular responses namely thymo-
cyte proliferation and LM cytotoxicity. The antibody des-
cribed here may not only enable further clinical trials with
TNF< but may have application in cancers where circulating
TNFa levels are high and evidence of coagulopathy is appar-
ent.
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